Mr. Abramson was named to the Calysta Advisory Board in 2015. He is currently a Principal in SDA Ventures LLC, a firm that advises emerging growth, middle-market companies and multi national companies primarily in the health and wellness, nutritional products, food ingredients and food service on matters including corporate development, business acquisition, customer relationships, growth strategies and corporate finance.
Mr. Abramson serves as an Operating Partner to the global private equity investment firm of Paine & Partners to identify and execute investment opportunities in the global human and animal food and nutritional products industries.
From 2003 to 2011, Mr. Abramson worked at Martek Biosciences Corporation (NASDAQ: MATK), serving as President of the Company beginning in 2006. Martek is a leader in the innovation, development, production and sale of high-value products from microbial sources that promote health and wellness through nutrition. The Company’s technology platform consisted of its core expertise, broad experience and proprietary technology in areas such as microbial biology, algal genomics, fermentation and downstream processing. This technology platform resulted in Martek’s development of a number of products, including its flagship brand, life’sDHA™, a sustainable and vegetarian source of algal DHA (Docosahexaenoic acid) important for brain, heart and eye health. The product is now a branded ingredient in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements and animal feeds. During Mr. Abramson’s tenure, market penetration grew to 99.5% in its core U.S. infant formula business. Mr. Abramson graduated from George Washington University in 1975, where he obtained a Bachelor of Business Administration in accounting. He received a Juris Doctor Degree, with honors, from the University of Maryland School of Law in 1978. Mr. Abramson is a member of the Maryland Bar.
William Haseltine, Ph.D., Chairman
William A. Haseltine, Ph.D. became a scientific advisor to Calysta in 2013. He is Chairman and President of ACCESS Health International, Inc (www.accessh.org) a foundation that supports access to affordable, high quality health services in low, middle and high income countries. He is also President of the Haseltine Foundation for Science and the Arts. He was a professor at Harvard Medical School, The Dana Farber Cancer Institue, and the Harvard School of Public Health. He is known for his pioneering work on cancer, HIV/AIDS and genomics. He is the Founder of Human Genome Sciences, Inc and served as the Chairman and CEO of the Company. He is a member of the Advisory Board of the IE University, Madrid, the Advisory Council for the Koch Institute of MIT and the Life Sciences Foundation, a member of the Advisory Board of the Ragon Institute, the Innovation Council of NYU Shanghai University, a member of the Dean’s Council and the Advisory Board of the FXB Center for Health and Human Rights at the Harvard School of Public Health. He is a Lifetime Governor of the New York Academy of Sciences and a member of the Board of AID for AIDS International. He is a member of the Board of Trustees of the Brookings Institution, and a member of the Council on Foreign Relations. He is a member of the Advisory Board of the Metropolitan Opera, a member of the Director’s Council of the Museum of Modern Art, a patron of the Metropolitan Museum of New York, the Whitney Museum, the Guggenheim Museum, the Whitney Museum a member of Board of Directors of the Young Concert Artists, Inc. and the Youth Orchestra of the Americas.
David Maki became a scientific advisor to Calysta in 2013. Mr. Maki has been involved in life science organizations for over 30 years and co-founded Altitude Life Science Ventures, a venture capital firm that seeks to identify and support early stage life science companies. Prior to founding Altitude, he served as a Principal with Perennial Ventures, and as a Vice President with Tredegar Investments. He previously spent almost two decades in intellectual property law, focusing on IP strategic planning for life science companies. He served as the senior partner within his firm’s biotechnology group, which represented more than 60 life science companies in a variety of disciplines, including protein and small molecule therapeutics, medical devices, diagnostic instrumentation, and bioinformatics. During his tenure, he also held the positions of Managing Partner and Financial Partner. Mr. Maki is known as an industry expert in the development and execution of intellectual property strategies in the life sciences arena. He has served as a Board member for a number of life science companies, and on the Washington Biotechnology Advisory Committee. He currently serves as an independent Director on the Board of Pulmatrix, Inc. and is Chairman of the Board of the Infectious Disease Research Institute.